Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced it has received a U.S. patent for its proprietary Guardian™ Technology.

 “The newly issued patent covers our proprietary Guardian Technology which has successfully been tested in clinical studies,” said Karsten Lindhardt, Ph.D., chief scientific officer of Egalet. “This issuance adds to our growing patent portfolio around our Guardian Technology which was the basis for our FDA approved product, ARYMO ER.”

The patent covers the Guardian Technology two-component tablet architecture which provides precise drug delivery and can confer abuse-deterrent properties. The United States Patent and Trademark Office (USPTO) has issued patent number 9,884,029 covering Egalet-002. The patent offers protection through March 2024.

Egalet has been granted a total of 20 U.S. patents and 59 patents outside of the U.S. that cover Guardian Technology and its product candidates.